ECE2022 Rapid Communications Rapid Communications 11: Thyroid 2 (7 abstracts)
Altered expression profiles of miR-22-5p and miR-142-3p display Hashimoto´s disease and are associated with thyroid antibodies
Olivia Trummer 1 , Ines Fößl 1 , Natascha Schweighofer 1,2 , Edi Arifi 1 , Christoph Haudum 1,2 , Sharmaine Reintar 1,2 , Stefan Pilz 1 , Verena Theiler-Schwetz 1 , Christian Trummer 1 , Andreas Zirlik 3 , Albrecht Schmidt 3 , Caterina Colantonio 3 , Ewald Kolesnik 3 , Nicolas Verheyen 3 , Thomas Pieber 1,2 & Barbara Obermayer-Pietsch 1
1Medical University of Graz, Division of Endocrinology and Diabetology, Graz, Austria; 2Center for Biomarker Research in Medicine, Graz, Austria; 3Medical University of Graz, Department of Cardiology, University Heart Center Graz, Graz, Austria
Background: Hashimoto’s thyroiditis (HT), the most prevalent autoimmune disorder of the thyroid (AITD) is characterized by the presence of circulating autoantibodies, induced by a not fully understood dysregulation of the immune system. MicroRNAs (miRNAs) are small noncoding RNAs, which can play a pivotal role in immune functions and the development of autoimmunity. The aim of the present investigation was to evaluate whether a panel of nine selected miRNAs differs in serum expressions of patients with HT and to analyse possible relations to thyroid antibody levels.
Methods: Participants of the BioPersMed cohort (n=1022), an ongoing single-centre, prospective, observational study to evaluate novel biomarkers for the assessment of cardiovascular and common metabolic diseases, were screened for previously diagnosed HT patients (n=27) as well as age and sex matched participants suitable as healthy controls (n=22). Thyroid function and common autoantibodies were evaluated by serum levels of thyroid stimulating hormone (TSH), free triiodothyronine (fT3), free thyroxine (fT4), thyroid peroxidase autoantibody (TPOAb) as well as thyroglobulin autoantibodies (TgAb), determined by luminescence immunoassays (Siemens, Erlangen, Germany). MiRNA profiles were analysed in the selected samples using quantitative reverse transcription polymerase chain reaction (qRT-PCR).
Results: Systemic expressions of miR-21-5p, miR-22-3p, miR-22-5p, miR-142-3p, miR-146a-5p and miR-451 were significantly upregulated in patients with HT (P<0.01, respectively) and indicate HT in receiver-operating characteristic (ROC) analysis with an area under the curve of at least 0.76 (95% confidence interval 0.61-0.91) for miR-22-5p. Subgroup analyses within HT patients showed significantly higher miRNA expression for miR-22-5p and miR-142-3p in HT patients with higher thyroid antibody levels (TgAb and/or TPOAb >60 U/ml, n=13) as compared to HT patients with lower thyroid antibody levels (TgAb and/or TPOAb <60 U/ml, n=11).
Conclusion: Upregulated systemic expression levels of miR-22-5p and miRNA-142-3p indicate HT and were related with higher levels of thyroid antibodies suggesting a contribution to the pathogenesis of HT.
References
1. Trummer, O.; Foessl, I. Schweighofer, N.; Arifi, E.; Haudum, C.W.; Reintar, S.; Pilz, S.; Theiler-Schwetz, V.; Trummer, C.;Zirlik, A.; et al. Expression Profiles of miR-22-5p and miR-142-3p Indicate Hashimoto’s Disease and Are related to Thyroid Antibodies. Genes 2022, 13, 171. https://doi.org/10.3390/genes13020171.
Volume 81
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more